Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Keryx Biopharmaceuticals    KERX   US4925151015

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Keryx Biopharmaceuticals : KERX, ARIA, PDLI added to BioStock Watch List at GSR

05/14/2013 | 09:35am US/Eastern
Recommend:
0

New York, NY -- (ACCESSWIRE) -- 05/14/2013 -- Growing Stock Report initiates a Biotech Watch List adding Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), PDL BioPharma, Inc. (NASDAQ:PDLI), and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) a biopharmaceutical company that focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States closed up in its previous session (+6.45%) on 4,785,770 shares traded. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) is currently up (+483.33%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their Biotech Gainers Watch List and Investor Poll.

To see what other Investors are saying about Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=KERX&SubId=AW

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients closed up in its previous session (+5.58%) on 2,928,742 shares traded after ARIAD Announced to Present at UBS Global Healthcare Conference on Monday, May 20, 2013. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently up (+14.01%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their Biotech Gainers Watch List and Investor Poll.

To see what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=ARIA&SubId=AW

PDL BioPharma, Inc. (NASDAQ:PDLI) a company that engages in intellectual property asset management and patent portfolio and related assets investment activities closed up in its previous session (+4.98%) on 3,224,150 shares traded after TheStreet Ratings rated PDL BioPharma as a Buy. PDL BioPharma, Inc. (NASDAQ:PDLI) is currently up (+32.47%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their Biotech Gainers Watch List and Investor Poll.

To see what other Investors are saying about PDL BioPharma, Inc. (NASDAQ:PDLI)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=PDLI&SubId=AW

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a biopharmaceutical company that focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders closed up in its previous session (+5.66%) on 3,084,480 shares traded after a Roth Capital Partners analyst said he thinks the company has become a more attractive target for a takeover. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is currently up (+885.38%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their Biotech Gainers Watch List and Investor Poll.

To see what other Investors are saying about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=ACAD&SubId=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.
Contact Info:
Growing Stock Report
editor@GrowingStockReport.com


© Accesswire 2013
Recommend :
0
React to this article
Latest news on KERYX BIOPHARMACEUTICALS
4d ago KERYX BIOPHARMACEUTICALS : Strengthens Leadership Team With Key Additions in Sal..
4d ago KERYX BIOPHARMACEUTICALS : Strengthens Leadership Team With Key Additions in Sal..
04/09 KERYX BIOPHARMACEUTICALS : DGAP-News: GlobeNewswire Press Release: Keryx Biophar..
04/09 KERYX BIOPHARMACEUTICALS : Announces Zerenex(TM) (Ferric Citrate Coordination Co..
04/09 GlobeNewswire Press Release: Keryx Biopharmaceuticals, Inc. (GlobeNewswire Pr..
04/02 KERYX BIOPHARMACEUTICALS : Announces EMA Validation of Marketing Authorization A..
04/02 KERYX BIOPHARMACEUTICALS : Announces EMA Validation of Marketing Authorization A..
04/01 KERYX BIOPHARMACEUTICALS : News of Delayed Medicare Policy Spikes Keryx Biopharm..
03/17 KERYX BIOPHARMACEUTICALS' : Zerenex(TM) Data Selected for Poster Presentation at..
03/17 KERYX BIOPHARMACEUTICALS' : Zerenex(TM) Data Selected for Poster Presentation at..
Advertisement
Chart
Duration : Period :
Keryx Biopharmaceuticals Technical Analysis Chart | KERX | US4925151015 | 4-Traders
Income Statement Evolution
Keryx Biopharmaceuticals : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF